Article Text
PDFReview
Disease modification in multiple sclerosis: an update
Abstract
Although there has been unequivocal progress in the development of treatments for multiple sclerosis over the last 20 years, currently licensed treatments have demonstrated convincing effects on disease course only with reference to relapse frequency. This review summarises the progress made, highlights the indications for, and limitations of, current disease-modifying therapies and discusses some interventions currently in development.
- Multiple Sclerosis
- Pharmacology
Statistics from Altmetric.com
Linked Articles
- Editors' choice
Read the full text or download the PDF:
Other content recommended for you
- Update on disease-modifying therapies for multiple sclerosis
- Disease modifying therapies for relapsing multiple sclerosis
- Multiple sclerosis and the risk of infection: Association of British Neurologists consensus guideline
- Effects of multiple sclerosis disease-modifying therapies on employment measures using patient-reported data
- Disease-modifying therapies for multiple sclerosis
- Switching patients at high risk of PML from natalizumab to another disease-modifying therapy
- Systematic literature review and network meta-analysis in highly active relapsing–remitting multiple sclerosis and rapidly evolving severe multiple sclerosis
- ▼Dimethyl fumarate for relapsing-remitting multiple sclerosis
- ▼Teriflunomide for multiple sclerosis
- Impact of drug diversity on treatment effectiveness in relapsing-remitting multiple sclerosis (RRMS) in Germany between 2010 and 2018: real-world data from the German NeuroTransData multiple sclerosis registry